AG˹ٷ

STOCK TITAN

[6-K] Cybin Inc. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Riscrivi il testo seguente:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세�:
Réécrivez le texte suivant :
Schreiben Sie den folgenden Text um:
Positive
  • None.
Negative
  • None.
Riscrivi il testo seguente:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세�:
Réécrivez le texte suivant :
Schreiben Sie den folgenden Text um:

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June, 2025.
Commission File Number: 001-40673


Cybin Inc.
(Exact Name of Registrant as Specified in Charter)

100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F

INCORPORATION BY REFERENCE
Exhibits 99.1 - 99.3 of this Form 6-K of Cybin Inc. (the "Company") are hereby incorporated by reference into the Registration Statement on Form F-10 (File No. 333-284173) of the Company, as amended or supplemented.





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CYBIN INC.
(Registrant)
 
Date:June 30, 2025By:
/s/ Doug Drysdale    
Name:Doug Drysdale
Title:Chief Executive Officer





EXHIBIT INDEX


99.1
Registration Rights Agreement dated June 30, 2025
99.2
Securities Purchase Agreement dated June 30, 2025
99.3
Form of Convertible Note


Cybin Inc

NYSE:CYBN

CYBN Rankings

CYBN Latest News

CYBN Stock Data

164.85M
18.64M
238.24%
41.95%
5.19%
Biotechnology
Healthcare
Canada
Toronto